Literature DB >> 20878993

Catechol-O-methyltransferase val158met and cognitive function in Parkinson's disease.

Jeroen Hoogland1, Rob M A de Bie, Caroline H Williams-Gray, Dino Muslimović, Ben Schmand, Bart Post.   

Abstract

Cognitive dysfunction is one of the most incapacitating non-motor symptoms of Parkinson's disease (PD). Some cognitive deficits are thought to be related to abnormal dopamine homeostasis. The latter is influenced by catechol-O-methyltransferase (COMT), an enzyme that degrades dopamine. Previous research suggests a relationship between the COMT val158met functional polymorphism (SNP) and measures of executive function. We evaluated this hypothesis in a cohort of PD patients with an extensive neuropsychological test battery. Cognitive assessment and COMT genotyping were performed in 153 early PD patients from outpatient clinics general hospitals in the Netherlands. Our results do not support a direct effect of COMT val158met genotype on performance on neuropsychological measures of attention and executive function, but they suggest that genotype may interact with dopaminergic medication use to influence cognitive ability.
© 2010 Movement Disorder Society.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20878993     DOI： 10.1002/mds.23319

Source DB:  PubMed          Journal:  Mov Disord        ISSN： 0885-3185            Impact factor:   10.338


  16 in total

1.  Association of Catechol-O-methyltransferase val/met polymorphism with cognitive function in Gilles de la Tourette syndrome patients.

Authors:  Weidong Ji; Ning Li; Kang Ju; Hong Zheng; Chuang Yang; Ping Xu; Silu Chen; Aiai Cao; Xue Chen; Lanting Guo
Journal:  Neurol Sci       Date:  2014-11-04       Impact factor: 3.307

2.  Large-scale exploratory genetic analysis of cognitive impairment in Parkinson's disease.

Authors:  Ignacio F Mata; Catherine O Johnson; James B Leverenz; Daniel Weintraub; John Q Trojanowski; Vivianna M Van Deerlin; Beate Ritz; Rebecca Rausch; Stewart A Factor; Cathy Wood-Siverio; Joseph F Quinn; Kathryn A Chung; Amie L Peterson-Hiller; Alberto J Espay; Fredy J Revilla; Johnna Devoto; Dora Yearout; Shu-Ching Hu; Brenna A Cholerton; Thomas J Montine; Karen L Edwards; Cyrus P Zabetian
Journal:  Neurobiol Aging       Date:  2017-04-20       Impact factor: 4.673

3.  Mid-frontal theta activity is diminished during cognitive control in Parkinson's disease.

Authors:  Arun Singh; Sarah Pirio Richardson; Nandakumar Narayanan; James F Cavanagh
Journal:  Neuropsychologia       Date:  2018-05-23       Impact factor: 3.139

4.  Methylphenidate : a treatment for Parkinson's disease?

Authors:  David Devos; Caroline Moreau; Arnaud Delval; Kathy Dujardin; Luc Defebvre; Regis Bordet
Journal:  CNS Drugs       Date:  2013-01       Impact factor: 5.749

Review 5.  What can biomarkers tell us about cognition in Parkinson's disease?

Authors:  Brit Mollenhauer; Lynn Rochester; Alice Chen-Plotkin; David Brooks
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

Review 6.  Genetic Variation and Neuroplasticity: Role in Rehabilitation After Stroke.

Authors:  Jill Campbell Stewart; Steven C Cramer
Journal:  J Neurol Phys Ther       Date:  2017-07       Impact factor: 3.649

7.  Genetic influences on cognitive decline in Parkinson's disease.

Authors:  James F Morley; Sharon X Xie; Howard I Hurtig; Matthew B Stern; Amy Colcher; Stacy Horn; Nabila Dahodwala; John E Duda; Daniel Weintraub; Alice S Chen-Plotkin; Vivianna Van Deerlin; Dana Falcone; Andrew Siderowf
Journal:  Mov Disord       Date:  2012-02-16       Impact factor: 10.338

Review 8.  Functional brain networks and abnormal connectivity in the movement disorders.

Authors:  Kathleen L Poston; David Eidelberg
Journal:  Neuroimage       Date:  2011-12-21       Impact factor: 6.556

9.  Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease.

Authors:  Caroline Moreau; Sayah Meguig; Jean-Christophe Corvol; Julien Labreuche; Francis Vasseur; Alain Duhamel; Arnaud Delval; Thomas Bardyn; Jean-Christophe Devedjian; Nathalie Rouaix; Gregory Petyt; Christine Brefel-Courbon; Fabienne Ory-Magne; Dominique Guehl; Alexandre Eusebio; Valérie Fraix; Pierre-Jean Saulnier; Ouhaid Lagha-Boukbiza; Frank Durif; Mirela Faighel; Caroline Giordana; Sophie Drapier; David Maltête; Christine Tranchant; Jean-Luc Houeto; Bettina Debû; Jean-Philippe Azulay; François Tison; Alain Destée; Marie Vidailhet; Olivier Rascol; Kathy Dujardin; Luc Defebvre; Régis Bordet; Bernard Sablonnière; David Devos
Journal:  Brain       Date:  2015-03-23       Impact factor: 13.501

10.  Dopamine effects on memory load and distraction during visuospatial working memory in cognitively normal Parkinson's disease.

Authors:  Ece Bayram; Irene Litvan; Brenton A Wright; Cailey Grembowski; Qian Shen; Deborah L Harrington
Journal:  Neuropsychol Dev Cogn B Aging Neuropsychol Cogn       Date:  2020-10-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.